Till now, several molecular target agents, such as the tyrosine kinase inhibitor sunitinib, the VEGFRs inhibitor pazopanib, and the mTOR inhibitors temsirolimus and everolimus, have been approved to treat patients with advanced RCC. The gene discussed is MTOR; the disease is renal cell adenocarcinoma.